Free Access
Med Sci (Paris)
Volume 24, Number 10, Octobre 2008
Page(s) 804 - 806
Section Nouvelles
Published online 15 October 2008
  1. CASCADE Collaboration. Determinants of survival following HIV-1 seroconversion after the introduction of HAART. Lancet 2003; 362 : 1267–74. [Google Scholar]
  2. Van Sighem A, Danner S, Ghani AC, et al. Mortality in patients with successful initial response to highly active antiretroviral therapy is still higher than in non-HIV-Infected individuals. J Acquir Immune Defic Syndr 2005; 40 : 212–8. [Google Scholar]
  3. Chêne G, Sterne JA, May M, et al. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy : analysis of prospective studies. Lancet 2003; 362 : 679–86. [Google Scholar]
  4. Lewden C, Chêne G, Morlat P, et al. HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long term combination antiretroviral therapy reach same mortality rates as the general population. J Acquir Immune Defic Syndr 2007; 46 : 72–7. [Google Scholar]
  5. The data collection on adverse events of anti-HIV drugs study group. Liver-related deaths in persons infected with the human immunodeficiency virus : the DAD study. Arch Intern Med 2006; 166 : 1632–41. [Google Scholar]
  6. Gras L, Kesselring AM, Griffin JT, et al. CD4 Cell counts of 800 cells/mm3 or greater after 7 years of highly active antiretroviral therapy are feasible in most patients starting with 350 cells/mm3 or greater. J Acquir Immune Defic Syndr 2007; 45 : 183–92. [Google Scholar]
  7. Yéni. Prise en charge médicale des personnes infectées par le VIH. Rapport 2006. Recommandations du groupe d’experts. 2006 [cited 2007 march 2007]. Available from : [Google Scholar]
  8. Phillips AN, Gazzard BG, Clumeck N, Losso MH, Lundgren JD. When should antiretroviral therapy for HIV be started ? Br Med J 2007; 334 : 76–8. [Google Scholar]
  9. The DAD Study Group. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356 : 1723–35. [Google Scholar]
  10. Capeau J, Caron M, Vigouroux C, et al. Les lipodystrophies secondaires aux traitements antirétroviraux de l’infection par le VIH. Med Sci (Paris) 2006; 22 : 531–6. [Google Scholar]
  11. Moatti JP, Spire B. Les enjeux économiques et sociaux de l’infection par le VIH à l’ère des multithérapies antirétrovirales : apports des sciences humaines et sociales. Med Sci (Paris) : 2003; 19 : 878–84. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.